Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1.
Xu, K., Acharya, P., Kong, R., Cheng, C., Chuang, G.Y., Liu, K., Louder, M.K., O'Dell, S., Rawi, R., Sastry, M., Shen, C.H., Zhang, B., Zhou, T., Asokan, M., Bailer, R.T., Chambers, M., Chen, X., Choi, C.W., Dandey, V.P., Doria-Rose, N.A., Druz, A., Eng, E.T., Farney, S.K., Foulds, K.E., Geng, H., Georgiev, I.S., Gorman, J., Hill, K.R., Jafari, A.J., Kwon, Y.D., Lai, Y.T., Lemmin, T., McKee, K., Ohr, T.Y., Ou, L., Peng, D., Rowshan, A.P., Sheng, Z., Todd, J.P., Tsybovsky, Y., Viox, E.G., Wang, Y., Wei, H., Yang, Y., Zhou, A.F., Chen, R., Yang, L., Scorpio, D.G., McDermott, A.B., Shapiro, L., Carragher, B., Potter, C.S., Mascola, J.R., Kwong, P.D.(2018) Nat Med 24: 857-867
- PubMed: 29867235 
- DOI: 10.1038/s41591-018-0042-6
- Primary Citation of Related Structures:  
5TKK, 5TKJ, 6CDP, 6CDO, 6CDI, 6CDM, 6CDE - PubMed Abstract: 
A central goal of HIV-1 vaccine research is the elicitation of antibodies capable of neutralizing diverse primary isolates of HIV-1. Here we show that focusing the immune response to exposed N-terminal residues of the fusion peptide, a critical compo ...